Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
LDN 212854 is a potent ALK inhibitor (IC50 values are 1.3, 2.4, 85.8, 2,133 and 9,276 nM for ALK2, ALK1, ALK3, ALK4 and ALK5, respectively). Exhibits selectivity for ALK2 over ALK4 and ALK5 in cellular assays. Inhibits heterotopic ossification in a mutant ALK2 mouse model of fibrodysplasia ossificans progressiva. Also exhibits activity against RIPK2, ABL1 and PDGFR-β (IC50 values < 100 nM).
Sold for research purposes under exclusive agreement from The Brigham and Women's Hospital Inc. US patent 14/776,302
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Mohedas et al (2013) Development of an ALK2-biased BMP type I receptor kinase inhibitor. ACS Chem.Biol. 8 1291 PMID: 23547776
Keywords: LDN 212854, LDN 212854 supplier, LDN212854, ALK, inhibitors, inhibits, potent, in, vivo, active, BMP1, ALK2, bone, morphogenetic, protein, type, I, BMP, and, Other, Activin, Receptors, 6151, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for LDN 212854.
There are currently no reviews for this product. Be the first to review LDN 212854 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Written by Kirsty E. Clarke, Victoria B. Christie, Andy Whiting and Stefan A. Przyborski, this review provides an overview of the use of small molecules in the control of stem cell growth and differentiation. Key signaling pathways are highlighted, and the regulation of ES cell self-renewal and somatic cell reprogramming is discussed. Compounds available from Tocris are listed.
Stem cells have potential as a source of cells and tissues for research and treatment of disease. This poster summarizes some key protocols demonstrating the use of small molecules across the stem cell workflow, from reprogramming, through self-renewal, storage and differentiation to verification. Advantages of using small molecules are also highlighted.